Valeant Pharmaceuticals Shares Jump on Rumoured Deal

This company is going to pull off a massive deal one way or the other.

| More on:
The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Shares of Valeant Pharmaceuticals (TSX:VRX,NYSE:VRX) are surging on this Friday afternoon.  Currently up 13% (was up by 17%), the stock caught fire after it was reported that the company is close to a deal to acquire Bausch & Lomb Holdings from Warburg Pincus, a private equity firm.

This is the second whale of a deal that Valeant has been rumoured to be close to sealing in the past month.  Valeant was apparently close to acquiring generic drug maker Actavis Inc. in a deal that would have topped the $13 billion mark.  Actavis’ recent purchase of Warner Chilcott helped pour cold water on the Valeant angle.

Why’s the stock up?

There are two contributing reasons for today’s surge.  One, growth oriented investors were probably ticked off when the apparent Actavis deal fell through.  Now that another big “growth” opportunity is on the table, their mood has shifted and they’re back in love with this serial acquirer.

Another reason is that there is a sizeable amount of institutional money in this country that is managed by those who may call themselves “active managers”, but in reality are nothing more than closet indexers.  They don’t like to stray from the safety of their sacred benchmark, the S&P/TSX Composite.

Valeant essentially makes up the entire Healthcare sector in the S&P/TSX Composite Index and therefore when it jumps, it hurts the relative return of all investors who are “underweight” this sector.  They are forced to buy shares and reduce this underweight exposure to help dull the pain.  Especially as we approach month end, when performance stats are logged.

Why the stock shouldn’t be up

Valeant has been on an acquisition spree since 2010 and has racked up a pile of debt.  If more debt is added to complete a deal of this size, it could lead to significant issues down the road if interest rates don’t co-operate.

Also, private equity folks aren’t the dullest knives in the drawer.  If they’re indeed selling, they’re doing it for a reason.  Either Valeant is over-paying or there is something wrong with Bausch and Lomb.  Given Warburg Pincus bought B+L for just $4.5 billion in 2007, which was a pretty frothy time in its own right for private equity deals, a $9 billion price tag certainly brings the over-pay scenario into play.

Foolish Takeaway

Serial acquirers have a knack for making spread-sheet models look fantastic.  The theory and reality behind this strategy however can have dire implications for investors.  Valeant is currently a market darling.  The financial risk tied to this name however could turn it into a goat very quickly.

The Motley Fool’s Special Free Report3 U.S. Stocks Every Canadian Should Own” profiles 3 of the world’s greatest businesses – where financial risk is not even a consideration.  To download a copy of this report at no charge, simply click here now.

Follow us on Twitter and Facebook for the latest in Foolish investing.

Fool contributor Iain Butler does not own shares in any of the companies mentioned at this time.  The Motley Fool has no positions in the stocks mentioned above.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing

funds, money, nest egg
Dividend Stocks

TFSA Passive Income: 2 Great Canadian Dividend Stocks for Retirees to Buy Now

Retirees seeking reliable passive income can now buy top TSX dividend stocks at cheap prices.

Read more »

man window buildings
Stocks for Beginners

Foolish Beginners: 1 Stock Pick to Buy Now for a $6,000 TFSA

Brookfield Asset Management (TSX:BAM.A)(NYSE:BAM) stock looks cheap as shares regain their footing.

Read more »

data analyze research
Dividend Stocks

Earn Monthly Passive Income: 2 Hot Dividend Stocks in Canada to Buy Now and Hold Forever

These two hot dividend stocks could help you to earn stable monthly passive income in Canada.

Read more »

Human Hand Placing A Coin On Increasing Coin Stacks In Front Of House
Dividend Stocks

Be a Landlord: Top 2 REITs (With Monthly Dividends) I’d Buy and Forget

You can be a landlord and earn monthly dividends for the rest of your life. All you need is the…

Read more »

Target. Stand out from the crowd
Investing

3 Canadian Stocks to Buy That Beat Their Earnings Expectations This Week

If you're looking for top Canadian stocks to buy, here are three impressive companies that continue to perform well in…

Read more »

A stock price graph showing declines
Energy Stocks

2 Cheap Canadian Stocks That Likely Won’t Be on Sale For Much Longer

These two Canadian stocks are close to returning to all-time highs. Don’t miss your chance to take advantage of these…

Read more »

A worker gives a business presentation.
Dividend Stocks

Got $5,000? 3 Stocks to Hold for the Next 20 Years

New investors don’t need tens of thousands to start a portfolio. Here are three stocks to hold for the next…

Read more »

canadian energy oil
Energy Stocks

3 Rising Energy Stocks to Buy as Oil Hits 6-Month Low

Three rising energy stocks are strong buys today as their upward momentum is likely to continue due to the tight…

Read more »